IRCT20210614051576N1
Completed
Phase 1
Cell therapy using human placenta-derived mesenchymal stem cells(PLMSCs) in patients with Secondary progressive-MS(SPMS): clinical trial phase I
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Multiple sclerosis.
- Sponsor
- Tehran University of Medical Sciences
- Enrollment
- 5
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients with SPMS
- •Age between18–45 years
- •Disease duration of 2 \- 16 years
- •Patients who are taking Rituximab drugs
Exclusion Criteria
- •Pregnant patients
- •Patients with positive results from screening tests (HBV, HCV, HIV, HTLV)
- •Patients with other systemic problems.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Infusion of human-derived placental-derived mesenchymal stem cells in patients with acute liver failureIRCT20190717044241N1Tehran University of Medical Sciences5
Recruiting
Phase 1
Placental Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 1-2 Clinical TrialAcute Respiratory Distress Syndrome of COVID-19.COVID-19U07.1IRCT20200413047063N1Execution of Imam Khomeini's Order20
Recruiting
Phase 1
The effects of mesenchymal stem cells in COVID-19IRCT20200621047859N4Modiriat Atiye Bahman Company20
Active, not recruiting
Not Applicable
se of mesenchymal cells for the treatment of patients with respiratory syndrome caused by new coronavirusRBR-3fz9yrPaulo Roberto Slud Brofman
Recruiting
Phase 1
Cell therapy with use of mesenchymal stem cells in infertile women with Thin EndometriumIRCT20230222057500N1Tehran University of Medical Sciences10